Genetic Technologies is a globally focused life sciences company based in Australia.
Our aim is to establish a significant market share in the fast-growing molecular diagnostics market; specifically in oncology.
Find out about company announcements, latest shareholder newsletters and our recent activities in the news. more
For investor relations, please contact firstname.lastname@example.org
1 in 11 women will develop breast cancer in their lifetime. With a market potential of $600 million per annum, BREVAGen is a cost effective test that helps women assess their sporadic
breast cancer risk.